<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30916124</article-id><article-id pub-id-type="pmc">6436786</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2018-0261</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Effect of Preoperative Creatinine Levels on Mortality after Coronary
Artery Bypass Grafting Surgery: an Observational Study</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6921-3202</contrib-id><name><surname>de Oliveira</surname><given-names>Marcos Aur&#x000e9;lio Barboza</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="c1"/><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>dos Santos</surname><given-names>Carlos Alberto</given-names></name><xref ref-type="aff" rid="aff3">3</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Brandi</surname><given-names>Ant&#x000f4;nio Carlos</given-names></name><xref ref-type="aff" rid="aff3">3</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Dotta</surname><given-names>Ana Helena</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Botelho</surname><given-names>Paulo Henrique Husseini</given-names></name><xref ref-type="aff" rid="aff3">3</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>de Godoy</surname><given-names>Moacir Fernandes</given-names></name><xref ref-type="aff" rid="aff3">3</xref><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>Braile</surname><given-names>Domingo M.</given-names></name><xref ref-type="aff" rid="aff3">3</xref><role>MD, PhD</role></contrib></contrib-group><aff id="aff1">
<label>1</label> Hospital Amecor, Cuiab&#x000e1;, MT, Brazil.</aff><aff id="aff2">
<label>2</label> Hospital Femina Cuiab&#x000e1;, MT, Brazil.</aff><aff id="aff3">
<label>3</label> Hospital de Base S&#x000e3;o Jos&#x000e9; do Rio Preto (HB),
S&#x000e3;o Jos&#x000e9; do Rio Preto, SP, Brazil.</aff><author-notes><corresp id="c1">Correspondence Address: <bold>Marcos Aur&#x000e9;lio Barboza de
Oliveira</bold>, https://orcid.org/0000-0002-6921-3202, Rua Tijuca, 1028,
Condom&#x000ed;nio Portal da Mata - Sinop, MT, Brazil, Zip code: 78555901 P.O.
box 407. E-mail: <email>maboliveira@gmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Mar-Apr</season><year>2019</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Mar-Apr</season><year>2019</year></pub-date><volume>34</volume><issue>2</issue><fpage>149</fpage><lpage>155</lpage><history><date date-type="received"><day>30</day><month>8</month><year>2018</year></date><date date-type="accepted"><day>26</day><month>1</month><year>2019</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Introduction</title><p>Renal function is an independent risk factor for mortality among on-pump
coronary bypass grafting (ONCABG) patients. This association is well known
in the international literature, but there is a lack of knowledge of how
admission creatinine (AC) levels modulate each cardiovascular risk
factor.</p></sec><sec><title>Objective</title><p>The aim of this paper was to assess the effect of different AC levels on
mortality among ONCABG patients.</p></sec><sec><title>Methods</title><p>1,599 patients who underwent ONCABG between December 1999 and February 2006
at Hospital de Base in S&#x000e3;o Jos&#x000e9; do Rio Preto/SP-Brazil were
included. They were divided into quartiles according to their AC levels (QI:
0.2 &#x02264;AC &#x0003c; 1.0 mg/dL; QII: 1.0 &#x02264; AC &#x0003c; 1.2 mg/dL; QIII:
1.2 &#x02264; AC &#x0003c; 1.4 mg/dL; and QIV: 1.4 &#x02264; AC &#x02264; 2.6
mg/dL). Seven risk factors were then evaluated in each stratum.</p></sec><sec><title>Results</title><p>Mortality was higher in the QIV group than QI or QII groups. Factors such as
age (&#x02265; 65 years) and cardiopulmonary bypass (CPB) time (&#x02265; 115
minutes) in QIV, as well preoperative hospital stay (&#x02265; 5 days) in
QIII, were associated with higher mortality rates. Creatinine variation
greater than or equal to 0.4 mg/dL increased mortality rates in all groups.
The use of intra-aortic balloon pump and dialysis increased mortality rates
in all groups except for QII. Type I neurological dysfunction increased the
mortality rate in the QII and III groups.</p></sec><sec><title>Conclusion</title><p>Creatinine levels play an important role in ONCABG mortality. The combination
of selected risk factors and higher AC values leads to a worse prognosis. On
the other hand, lower AC values were associated with a protective effect,
even among elderly patients and those with a high CPB time.</p></sec></abstract><kwd-group><kwd>Kidney - Physiopathology</kwd><kwd>Coronary Artery Bypass</kwd><kwd>Risk Factors</kwd><kwd>Creatinine - Blood, Treatment Outcome</kwd></kwd-group></article-meta></front><body><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="42%" span="1"/><col width="5%" span="1"/><col width="5%" span="1"/><col width="42%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</th><th align="center" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">95% CI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= 95% confidence
interval</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">EOL</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Extreme outliar</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Admission
creatinine</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">IAB</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Intra-aortic
balloon</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CABG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary artery bypass
grafting</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ICU</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Intensive care unit</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CPB</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cardiopulmonary
bypass</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">IQI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Interquartile
interval</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">Cr Var</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">=Creatinine variation</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">MACCE</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Major adverse cardiac
and cerebrovascular events</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CV</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cardiovascular</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ONCABG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= On-pump coronary artery
bypass grafting</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CVD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cardiovascular
disease</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">OR</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= <italic>Odds
ratio</italic></td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">DATASUS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Brazilian Department of
Public Healthcare Data</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">Qs</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Quartiles</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Cardiovascular diseases (CVDs) are the main cause of death in Brazil. According to
the Brazilian Department of Public Healthcare Data (DATASUS), in 2014, there were
340,284 CVD-related deaths in the country, which represented approximately 23% of
all deaths in that year. Out of all cases of CVD, 60% involved ischemic diseases and
myocardial infarction<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>. The
Brazilian government spent BRL$13.5 billion on healthcare in that same year, and
approximately 2.5% of that amount was directly applied to coronary artery bypass
grafting (CABG) procedures alone or in combination with another procedure<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>.</p><p>In an attempt to decrease the mortality rate and hospital costs of cardiovascular
(CV) patients, a group of authors studied data from 132 centers from eight different
countries in Europe to identify risk factors in which they could predict a patient's
odds of dying. One of these initiatives, which is now used around the world, is
known as the EuroSCORE<sup>[<xref rid="r2" ref-type="bibr">2</xref>]</sup>. Although
EuroSCORE has been able to accurately predict mortality rates for European patients,
it has failed when applied to Brazilian patients<sup>[<xref rid="r3" ref-type="bibr">3</xref>]</sup>.</p><p>Lisboa et al.<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup> evaluated the
applicability of EuroSCORE II at their institution and concluded that EuroSCORE II
could not accurately foresee mortality rates for their patients; they decided to use
a local scoring system. Santos et al.<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup> assessed 1,628 on-pump coronary artery bypass grafting (ONCABG)
patients and found seven (pre-, intra- and postoperative) mortality risk factors and
established cutoff values for each of them for their local population. The behavior
of these risk factors is still unknown in cases in which the patient has a different
admission creatinine (AC) value, which is another important risk factor.</p><p>The aim of this paper was to assess the effect of different AC levels on mortality
among ONCABG patients.</p></sec><sec sec-type="methods"><title>METHODS</title><p>This study was approved by the local Ethics Committee under number 454,518, and
informed consent was waived due to the retrospective nature of the study.</p><p>From December 1999 to February 2006, 1,674 ONCABG patients from Hospital de Base of
the city of S&#x000e3;o Jos&#x000e9; do Rio Preto, S&#x000e3;o Paulo state, Brazil,
were consecutively enrolled. To mitigate bias, patients with incomplete follow-up
information who had undergone emergency surgery or who died during the surgery were
excluded; a total of 46 patients (2.7%) were therefore excluded from the initial
group.</p><p>We evaluated 1,628 patients and considered the following variables: use of
intra-aortic balloon (IAB), cardiopulmonary bypass (CPB) time, creatinine variation,
dialysis, type I neurological lesion, preoperative hospital stay, and age. The
definitions and explanations of these factors are as follows:</p><p>
<list list-type="bullet"><list-item><p>IAB: represents the whole number of implanted IABs, with no distinction
regarding the time of placement (pre- or intraoperative);</p></list-item><list-item><p>Creatinine variation: difference between AC and the highest creatinine
value recorded in the intensive care unit (ICU);</p></list-item><list-item><p>Type I neurological lesion: new and persistent focal motor deficit, coma,
seizures or new encephalic lesion as determined by computed tomography
or magnetic resonance imaging;</p></list-item><list-item><p>Mortality: death by any cause within 30 days of surgery.</p></list-item></list>
</p><p>Extreme outliers were used to exclude patients with ACs greater than the established
values, which were calculated using the following formula:</p><p>
<inline-formula><mml:math id="e01"><mml:mrow><mml:mstyle mathsize="12.0pt"><mml:mi>EOL</mml:mi><mml:mo>=</mml:mo><mml:mi>p</mml:mi><mml:mn>75</mml:mn><mml:mo>+</mml:mo><mml:mn>3</mml:mn><mml:mo>*</mml:mo><mml:mi>IQR</mml:mi></mml:mstyle></mml:mrow></mml:math></inline-formula>
</p><p>where EOL=extreme outlier; p75=75<sup>th</sup> percentile; and IQR=interquartile
range.</p><p>The EOL value found was 2.6 mg/dL. Based on this value, 29 additional patients were
excluded. The remaining 1,599 patients were separated into quartiles (Qs) based on
their AC:</p><p>
<list list-type="simple"><list-item><p>QI: 0.2 &#x02264; AC &#x0003c; 1 mg/dL;</p></list-item><list-item><p>QII: 1 &#x02264; AC &#x0003c; 1.2 mg/dL;</p></list-item><list-item><p>QIII: 1.2 &#x02264; AC &#x0003c; 1.4 mg/dL; and</p></list-item><list-item><p>QIV: 1.4 &#x02264; AC &#x02264; 2.6 mg/dL.</p></list-item></list>
</p><p>The risk factors and their respective cutoff points were extracted from the study by
Santos et al.<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup> and were used to
determine the mortality rate in each quartile. The risk factors and their cutoff
points were: age (65 years), preoperative hospital stay (5 days), CPB time (115
minutes), creatinine variation (0.4 mg/dL), presence of IAB, dialysis and type I
neurologic lesion.</p><sec><title>Statistical Analysis</title><p>Continuous and discrete variables were transformed into categorical data
according to each cutoff value (0=below cutoff value; 1=above cutoff value and
death=1; alive=0). Logistic regression analysis was performed for all of the
risk factors, and the <italic>P</italic> value was obtained.</p><p>Other <italic>P</italic> values were calculated using Fisher's exact test. The
type I error (&#x003b1;) was set at 5%, and all of the tests were two-tailed. The
<italic>odds ratio</italic> (OR) and the 95% confidence interval (95% CI)
were calculated. The statistical software used were GraphPad 3.0 and StatsDirect
1.9.15 for Windows<sup>TM</sup>.</p><p>The "n" value was not calculated due to the observational nature of the
study.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>Mortality rates in each AC stratum are shown in <xref ref-type="fig" rid="f1">Figure
1</xref>. The highest AC level-QIV-was associated with greater mortality when
compared to AC values in the QI group or in the QII group (<italic>P</italic>=0.0392
and <italic>P</italic>=0.0016, respectively). <xref rid="t1" ref-type="table">Tables
1</xref> to <xref rid="t4" ref-type="table">4</xref> show pre-, intra- and
postoperative risk factors in each AC stratum.</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Inter-stratum mortality.</p></caption><graphic xlink:href="rbccv-34-02-0149-g01"/></fig>
</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Mortality risk factors among ONCABG patients (n=336) with AC levels greater
than or equal to 0.2 and less than 1 mg/dL (QI).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Dead (23)</th><th align="center" rowspan="1" colspan="1">Alive (313)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th><th align="center" rowspan="1" colspan="1">OR (95% CI)</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">IAB</td><td align="center" rowspan="1" colspan="1">+</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">0.0169</td><td align="center" rowspan="1" colspan="1">5.00 (1.33-18.74)</td></tr><tr><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">299</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">CPB time</td><td align="center" rowspan="1" colspan="1">&#x02265;115 min</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">56</td><td align="center" rowspan="1" colspan="1">0.2775</td><td align="center" rowspan="1" colspan="1">1.79 (0.62-5.18)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x0003c;115 min</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">257</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Cr var</td><td align="center" rowspan="1" colspan="1">&#x02265;0.4 mg/dL</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">61</td><td align="center" rowspan="1" colspan="1">0.0091</td><td align="center" rowspan="1" colspan="1">3.67 (1.38-9.78)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x0003c;0.4 mg/dL</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">252</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Dialysis</td><td align="center" rowspan="1" colspan="1">+</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0.0062</td><td align="center" rowspan="1" colspan="1">28.15 (2.58-307.22)</td></tr><tr><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">312</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Neuro I</td><td align="center" rowspan="1" colspan="1">+</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">0.2077</td><td align="center" rowspan="1" colspan="1">2.87 (0.55-14.82)</td></tr><tr><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">304</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Adm - surg</td><td align="center" rowspan="1" colspan="1">&#x02265;5 days</td><td align="center" rowspan="1" colspan="1">14</td><td align="center" rowspan="1" colspan="1">152</td><td align="center" rowspan="1" colspan="1">0.4442</td><td align="center" rowspan="1" colspan="1">1.48 (0.54-4.08)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x0003c;5 days</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">161</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">&#x02265;65 years</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">112</td><td align="center" rowspan="1" colspan="1">0.3597</td><td align="center" rowspan="1" colspan="1">1.57 (0.59-4.14)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x0003c;65 years</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">201</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p>AC=admission creatinine; Adm - surg=preoperative hospital stay;
CI=confidence interval; CPB=cardiopulmonary bypass; Cr var=creatinine
variation; IAB=intra-aortic balloon; min=minutes; Neuro I=type I
neurological lesion; ONCABG=on-pump coronary artery bypass grafting;
OR=<italic>odds ratio</italic></p></fn></table-wrap-foot></table-wrap><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Mortality risk factors among ONCABG patients (n=396) with AC levels greater
than or equal to 1 and less than 1.2 mg/dL (QII).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Dead (21)</th><th align="center" rowspan="1" colspan="1">Alive (375)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th><th align="center" rowspan="1" colspan="1">OR (95% CI)</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">IAB</td><td align="center" rowspan="1" colspan="1">+</td><td align="center" rowspan="1" colspan="1">3</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">0.2297</td><td align="center" rowspan="1" colspan="1">2.73 (0.53-14.10)</td></tr><tr><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">349</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">CPB time</td><td align="center" rowspan="1" colspan="1">&#x02265;115 min</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">0.0997</td><td align="center" rowspan="1" colspan="1">2.78 (0.82-9.41)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x0003c;115 min</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">318</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Cr var</td><td align="center" rowspan="1" colspan="1">&#x02265;0.4 mg/dL</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1">0.0133</td><td align="center" rowspan="1" colspan="1">4.37 (1.35-14.06)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x0003c;0.4 mg/dL</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">317</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Dialysis</td><td align="center" rowspan="1" colspan="1">+</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0.068</td><td align="center" rowspan="1" colspan="1">17.36 (0.82-367.41)</td></tr><tr><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">374</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Neuro I</td><td align="center" rowspan="1" colspan="1">+</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">4</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.0001</td><td align="center" rowspan="1" colspan="1">73.55 (16.20-333.76)</td></tr><tr><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">371</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Adm - surg</td><td align="center" rowspan="1" colspan="1">&#x02265;5 days</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">171</td><td align="center" rowspan="1" colspan="1">0.9538</td><td align="center" rowspan="1" colspan="1">1.03 (0.31-3.43)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x0003c;5 days</td><td align="center" rowspan="1" colspan="1">9</td><td align="center" rowspan="1" colspan="1">204</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">&#x02265;65 years</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">118</td><td align="center" rowspan="1" colspan="1">0.7591</td><td align="center" rowspan="1" colspan="1">1.21 (0.35-4.14)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x0003c;65 years</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">257</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p>AC=admission creatinine; Adm - surg=preoperative hospital stay;
CI=confidence interval; CPB=cardiopulmonary bypass; Cr var=creatinine
variation; IAB=intra-aortic balloon; min=minutes; Neuro I=type I
neurological lesion; ONCABG=on-pump coronary artery bypass grafting;
OR=<italic>odds ratio</italic></p></fn></table-wrap-foot></table-wrap><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Mortality risk factors among ONCABG patients (n=378) with admission
creatinine levels greater than or equal to 1.2 and less than1.4 mg/dL
(QIII).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Dead (31)</th><th align="center" rowspan="1" colspan="1">Alive (347)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th><th align="center" rowspan="1" colspan="1">OR (95% CI)</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">IAB</td><td align="center" rowspan="1" colspan="1">+</td><td align="center" rowspan="1" colspan="1">7</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">0.014</td><td align="center" rowspan="1" colspan="1">4.86 (1.37-17.21)</td></tr><tr><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">24</td><td align="center" rowspan="1" colspan="1">332</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">CPB time</td><td align="center" rowspan="1" colspan="1">&#x02265;115 min</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">65</td><td align="center" rowspan="1" colspan="1">0.094</td><td align="center" rowspan="1" colspan="1">2.19 (0.87-5.52)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x0003c;115 min</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">282</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Cr var</td><td align="center" rowspan="1" colspan="1">&#x02265;0.4 mg/dL</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">0.0134</td><td align="center" rowspan="1" colspan="1">3.18 (1.27-7.99)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x0003c;0.4 mg/dL</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">290</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Dialysis</td><td align="center" rowspan="1" colspan="1">+</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">1</td><td align="center" rowspan="1" colspan="1">0.0008</td><td align="center" rowspan="1" colspan="1">62.67 (5.55-707.74)</td></tr><tr><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">346</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Neuro I</td><td align="center" rowspan="1" colspan="1">+</td><td align="center" rowspan="1" colspan="1">8</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">0.0038</td><td align="center" rowspan="1" colspan="1">5.85 (1.77-19.35)</td></tr><tr><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">336</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Adm - surg</td><td align="center" rowspan="1" colspan="1">&#x02265;5 days</td><td align="center" rowspan="1" colspan="1">19</td><td align="center" rowspan="1" colspan="1">150</td><td align="center" rowspan="1" colspan="1">0.0182</td><td align="center" rowspan="1" colspan="1">3.05 (1.20-7.72)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x0003c;5 days</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">197</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">&#x02265;65 years</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">121</td><td align="center" rowspan="1" colspan="1">0.0737</td><td align="center" rowspan="1" colspan="1">2.30 (0.92-5.77)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x0003c;65 years</td><td align="center" rowspan="1" colspan="1">10</td><td align="center" rowspan="1" colspan="1">226</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="TFN3"><p>AC=admission creatinine; Adm - surg=preoperative hospital stay;
CI=confidence interval; CPB=cardiopulmonary bypass time; Cr
var=creatinine variation; Neuro I=type I neurological lesion;
IAB=intra-aortic balloon; min=minutes; ONCABG=on-pump coronary artery
bypass grafting; OR=<italic>odds ratio</italic></p></fn></table-wrap-foot></table-wrap><table-wrap id="t4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Mortality risk factors among ONCABG patients (n=489) with admission
creatinine levels greater than or equal to 1.4 and less than 2.6 mg/dL
(QIV).</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">Dead (55)</th><th align="center" rowspan="1" colspan="1">Alive (434)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic></th><th align="center" rowspan="1" colspan="1">OR (95% CI)</th></tr></thead><tbody><tr><td align="left" rowspan="2" colspan="1">IAB</td><td align="center" rowspan="1" colspan="1">+</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">0.0013</td><td align="center" rowspan="1" colspan="1">3.88 (1.69-8.90)</td></tr><tr><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">408</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">CPB time</td><td align="center" rowspan="1" colspan="1">&#x02265;115 min</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="1" colspan="1">0.0039</td><td align="center" rowspan="1" colspan="1">2.60 (1.35-4.97)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x0003c;115 min</td><td align="center" rowspan="1" colspan="1">34</td><td align="center" rowspan="1" colspan="1">354</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Cr var</td><td align="center" rowspan="1" colspan="1">&#x02265;0.4 mg/dL</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">151</td><td align="center" rowspan="1" colspan="1">0.039</td><td align="center" rowspan="1" colspan="1">2.00 (1.03-3.86)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x0003c;0.4 mg/dL</td><td align="center" rowspan="1" colspan="1">20</td><td align="center" rowspan="1" colspan="1">283</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Dialysis</td><td align="center" rowspan="1" colspan="1">+</td><td align="center" rowspan="1" colspan="1">11</td><td align="center" rowspan="1" colspan="1">12</td><td align="center" rowspan="1" colspan="1">0.0062</td><td align="center" rowspan="1" colspan="1">4.05 (1.48-11.06)</td></tr><tr><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">44</td><td align="center" rowspan="1" colspan="1">422</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Neuro I</td><td align="center" rowspan="1" colspan="1">+</td><td align="center" rowspan="1" colspan="1">5</td><td align="center" rowspan="1" colspan="1">18</td><td align="center" rowspan="1" colspan="1">0.6306</td><td align="center" rowspan="1" colspan="1">1.32 (0.41-4.20)</td></tr><tr><td align="center" rowspan="1" colspan="1">-</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">416</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Adm - surg</td><td align="center" rowspan="1" colspan="1">&#x02265;5 days</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">228</td><td align="center" rowspan="1" colspan="1">0.5023</td><td align="center" rowspan="1" colspan="1">1.23 (0.66-2.30)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x0003c;5 days</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">206</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><td align="left" rowspan="2" colspan="1">Age</td><td align="center" rowspan="1" colspan="1">&#x02265;65 years</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1">155</td><td align="center" rowspan="1" colspan="1">0.0101</td><td align="center" rowspan="1" colspan="1">2.27 (1.21-4.24)</td></tr><tr><td align="center" rowspan="1" colspan="1">&#x0003c;65 years</td><td align="center" rowspan="1" colspan="1">23</td><td align="center" rowspan="1" colspan="1">279</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td><td align="center" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn id="TFN4"><p>AC=admission creatinine; Adm - surg=preoperative hospital time;
CI=confidence interval;CPB=cardiopulmonary bypass; Cr var=creatinine
variation; IAB=intra-aortic balloon; min=minutes; Neuro I=type I
neurological lesion; ONCABG=on-pump coronary artery bypass grafting;
OR=<italic>odds ratio</italic></p></fn></table-wrap-foot></table-wrap><p>When the risk factors of the QI group were considered, there was no increase in
mortality associated with age, type I neurologic lesion, preoperative hospital stay,
or CPB time. However, IAB presented an OR of 5.00 (95% CI 1.33-18.74;
<italic>P</italic>=0.0169); dialysis was found to have an OR of 28.15 (95% CI
2.58-307.22; <italic>P</italic>=0.0062), and creatinine variation had an OR of 3.67
(95% CI 1.38-9.78; <italic>P</italic>=0.0091). The details are shown in <xref rid="t1" ref-type="table">Table 1</xref>.</p><p>In the QII group, neither age, CPB time, preoperative hospital stay, IAB, nor
dialysis were correlated with any increase in mortality. On the contrary, creatinine
variation had an OR of 4.37 (95% CI 1.35-14.06; <italic>P</italic>=0.0133), and the
type I neurological lesion had an OR of 73.55 (95% CI 16.20-333.76;
<italic>P</italic>&#x0003c;0.0001). More information can be found in <xref rid="t2" ref-type="table">Table 2</xref>.</p><p>When the QIII group was considered, there were no increases in mortality associated
with CPB time or age; however, IAB presented an OR of 4.86 (95% CI 1.37-17.21;
<italic>P</italic>=0.014), creatinine variation had an OR of 3.18 (95% CI
1.27-7.99; <italic>P</italic>=0.0134), dialysis had an OR of 62.67 (95% CI
5.55-707.74; <italic>P</italic>=0.0008), type I neurological lesion had an OR of
5.85 (95% CI 1.77-19.35; <italic>P</italic>=0.0038), and preoperative hospital stay
had an OR of 3.05 (95% CI 1.20-7.72; <italic>P</italic>=0.0182), as detailed in
<xref rid="t3" ref-type="table">Table 3</xref>.</p><p>When the QIV group was considered, no increase in mortality was found to be
associated with type I neurological lesions or with preoperative hospital stay. On
the contrary, IAB presented an OR of 3.88 (95% CI 1.69-8.90;
<italic>P</italic>=0.0013), CPB time had an OR of 2.60 (95% CI 1.35-4.97;
<italic>P</italic>=0.0039), creatinine variation had an OR of 2.00 (95% CI
1.03-3.86; <italic>P</italic>=0.039), dialysis had an OR of 4.05 (95% CI 1.48-11.06;
<italic>P</italic>=0.0062), and age had an OR of 2.27 (95% CI 1.21-4.24;
<italic>P</italic>=0.0101). Details can be found in <xref rid="t4" ref-type="table">Table 4</xref>.</p></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>This is an observational study that relied on a database. Despite this design, we
cannot underestimate its scientific value, particularly with regard to mortality
rates. Most importantly, we identified an increase in mortality rates as high as
112% between the QII group and the AC QIV group. There was no increase in mortality
rates among patients aged 65 years or older or whose CPB times were longer than or
equal to 115 minutes in the QI, II and III groups. Preoperative hospital stay of 5
days or longer was correlated with increased mortality rates only in the QIII group.
Creatinine variation greater than or equal to 0.4 mg/dL increased mortality rates in
all groups. Type I neurological lesions increased mortality in the QII group and in
the QIII group. Dialysis and IAB did not increase mortality in the QII group.</p><p>Increased preoperative creatinine is an independent risk factor known for morbidity
and mortality after cardiac surgery<sup>[<xref rid="r6" ref-type="bibr">6</xref>-<xref rid="r9" ref-type="bibr">9</xref>]</sup>. When AC was
considered in isolation in this study, mortality was found to increase as AC
increased. Significant differences were found between the QI group and the QIV
group, with an OR of 1.72 (95% CI 1.01-3.00; <italic>P</italic>=0.0392). Significant
differences were also found between the QII group and the QIV group, with an OR of
2.26 (95% CI 1.31-4.01; <italic>P</italic>=0.0016). These results are detailed in
<xref ref-type="fig" rid="f1">Figure 1</xref>. Similar findings were also
reported by Miceli et al.<sup>[<xref rid="r6" ref-type="bibr">6</xref>]</sup>, who
concluded that when creatinine clearance was less than 60 mL/min/1,73 m<sup>2</sup>,
mortality rates increased by 12% to 164%.</p><p>In our study, IAB insertion increased mortality rates in all AC strata, with the
exception of the QII group (<italic>P</italic>=0.22), a difference which was likely
due to the low incidence of deaths. The results from Rampersad et al.<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup> (meta-analysis with a total of
1,200 patients from 1997 to 2014) go in another direction. They stated that IAB
insertion actually decreases mortality rates (RR 0.48, 95% CI 0.30-0.76,
<italic>P</italic>&#x0003c;0.01) and major adverse cardiac and cerebrovascular events
(RR 0.67; 95% CI 0.54-0.84 <italic>P</italic>&#x0003c;0.001). In a detailed analysis, we
can see each paper included in that meta-analysis. Most part of those small papers
were inconclusive for mortality and major adverse cardiac and cerebrovascular events
(MACCE) and even some with high mortality rates, but when we put them together we
can achieve statistic significance. Even if we had enrolled 1,599 patients, an
observational study will never have the power to indicate whether a procedure is
definitely related to increased mortality. For this, we will need a clinical trial
or meta-analysis of clinical trials. Observational papers are very good at making
hypothesis and defining the local characteristics of our patients like we did
here.</p><p>CPB time increased mortality in our study in the QIV group. Otherwise, CPB time
between 115 and 188 minutes was not associated with an increase in mortality (188
minutes being the longest CPB time recorded in this study). Taniguchi et
al.<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup> and Rodrigues et
al.<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup> agree that longer
CPB time is correlated with increased mortality (over 90 and 120 minutes,
respectively).</p><p>Creatinine variation greater than or equal to 0.4 mg/dL increased the mortality rate
in every creatinine stratum. When this variation was associated with QI group,
mortality increased by 267% (OR 3.67; 95% CI 1.38-9.78) and, when creatinine
variation was associated in the QIV group, mortality increased by 100% (OR 2.00; 95%
CI 1.03-3.86). Machado et al.<sup>[<xref rid="r8" ref-type="bibr">8</xref>,<xref rid="r13" ref-type="bibr">13</xref>]</sup> and Santos et al.<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup> found similar results, reporting
increased mortality when creatinine variation was more than 0.3 mg/dL and 0.4 mg/dL,
respectively. The consistent increase in mortality when creatinine variation exceeds
0.4 mg/dL is quite important. Until now, this increase was known to be harmful to
patients, but the question remained regarding the greater risk between a patient
with AC 0.2 mg/dL whose creatinine increased to 0.6 mg/dL and a patient with AC 2.6
mg/dL whose creatinine increased to 3.0 mg/dL. Our results support the conclusion
that, when creatinine variation is higher than 0.4 mg/dL, mortality rates increase
regardless of the AC value.</p><p>In our study, dialysis was associated with increased mortality in almost all AC
strata. The only AC stratum in which the difference was not significant was that of
QII group, a difference that was likely due to the limited number of patients in
this group (<italic>P</italic>=0.06). In the other strata, OR was found between 4.05
and 62.67. These findings are in accordance with those of Chertow et al.<sup>[<xref rid="r14" ref-type="bibr">14</xref>]</sup>, who found that acute kidney
failure associated with dialysis is an independent risk factor for death, with an OR
of 27 (95% CI 22-34).</p><p>The prevalence of type I neurological lesion after ONCABG is approximately 2% to
6.1%. It is associated with chronic kidney injury, recent myocardial infarction,
cerebrovascular accident, carotid artery disease, peripheral vascular disease,
previous cardiac surgery, hypertension, diabetes, atrial fibrillation, preoperative
infection, age greater than 75 years, severe or moderate left ventricular
dysfunction, CPB time over 120 minutes, and massive transfusion<sup>[<xref rid="r15" ref-type="bibr">15</xref>,<xref rid="r16" ref-type="bibr">16</xref>]</sup>. According Stamou et al.<sup>[<xref rid="r15" ref-type="bibr">15</xref>]</sup>, the incidence of death associated with type I
neurological lesions is 4.18 times higher than among those who do not present this
type of neurological lesion. Our results determined a mortality rate that was 4.85
to 72.55 times higher, except for the QI group and the QIV group. These groups
likely differed because of the small number of patients (<italic>P</italic>=0.20 and
<italic>P</italic>=0.63, respectively). Taking into account the severity of this
type of lesion, which is generally associated with worse postoperative outcomes,
Santos et al.<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup> outlines some
protective measures to reduce its incidence, including minimal manipulation of the
aorta and maintenance of the highest gradient pressure during CPB, especially in
patients with a prior history of cerebrovascular accident.</p><p>The only group in which preoperative hospital stay was 5 days or longer was the QIII
group, with OR 3.05 (95% CI 1.20-7.72), <italic>P</italic>=0.0182. Our findings are
in accordance with those of Santos et al.<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>. These authors pointed out an increase in mortality with an
OR of 1.53 (95% CI 1.03-2.27; <italic>P</italic>=0.03). The hospital stay before
surgery may be associated with clinical severity, a correlation which suggests an
advanced degree of coronary involvement that may result in increased morbidity and
mortality rates in the postoperative period.</p><p>Naughton et al.<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup> found that age
(75 years or older) is an independent risk factor for early mortality (death within
fewer than 30 days), with an HR of 2.0 (95% CI 1.28-3.11), but that it is not an
independent risk factor for late mortality. In our study, age (65 years or older)
was associated with higher mortality rates only in the QIV group. Nevertheless,
mortality did not increase in the QI and QII groups, even among patients older than
65 years (the highest age in this study was 88 years old).</p><p>No other study in the literature seems to support an association between patients
with CPB time longer than 115 minutes or age above 65 years and an AC level less
than 1.4 mg/dL. Nevertheless, these results must be evaluated with caution, although
not with skepticism. If these results are found to be reproducible by other authors,
they may possibly change certain practices in cardiovascular surgery, leading us to
rethink the indication of faster ONCABG and the decision to disregard one or more
grafts. These results should also lead us to rethink some of the contraindications
for this type of surgery, especially for elderly patients. The analyses of these
variables in each creatinine stratum by other authors are necessary to confirm or
reject our findings.</p><sec><title>Limitations</title><p>This study has several limitations. It is based on a large institutional database
and results that were collected prospectively, and therefore we are unable to
access the influence of any variable outside the database. The observational
nature of this study makes it useful for formulating hypotheses, but the results
are not strong enough to change routines. Other papers are needed to certify our
findings.</p></sec></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>Creatinine levels play an important role in ONCABG mortality. The association between
selected risk factors and higher AC values leads to a worse prognosis. Conversely,
lower AC values were associated with a protective effect, even for elderly patients
and with longer CPB times.</p><table-wrap id="t6" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">MABO</td><td align="left" rowspan="1" colspan="1">Conception and design of the work; acquisition,
analysis, interpretation of data for the work; drafting the work and
revising it critically for important intellectual content; final
approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">CAS</td><td align="left" rowspan="1" colspan="1">Interpretation of data for the work; revising it
critically for important intellectual content; final approval of the
version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">ACB</td><td align="left" rowspan="1" colspan="1">Acquisition, analysis, interpretation of data for the
work; final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">AHD</td><td align="left" rowspan="1" colspan="1">Acquisition, analysis, interpretation of data for the
work; final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">PHHB</td><td align="left" rowspan="1" colspan="1">Acquisition, analysis, interpretation of data for the
work; final approval of the version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">MFG</td><td align="left" rowspan="1" colspan="1">Conception and design of the work; revising it
critically for important intellectual content; final approval of the
version to be published</td></tr><tr><td align="left" rowspan="1" colspan="1">DMB</td><td align="left" rowspan="1" colspan="1">Conception and design of the work; revising it
critically for important intellectual content; final approval of the
version to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at Hospital de Base S&#x000e3;o Jos&#x000e9; do Rio
Preto (HB), S&#x000e3;o Jos&#x000e9; do Rio Preto, SP, Brazil.</p></fn><fn fn-type="financial-disclosure"><p>No financial support.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ack><title>ACKNOWLEDGMENTS</title><p>We thank Dr. Renato Braz de Ara&#x000fa;jo for his priceless help in editing the final
manuscript and Danielle Deremo Cosimo for her English translation and language
revision services.</p></ack><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="webpage"><person-group person-group-type="author"><collab>Datasus: Departamento de Inform&#x000e1;tica do SUS</collab></person-group><comment>[Internet]</comment><source>Minist&#x000e9;rio da Sa&#x000fa;de: Datasus</source><year>c2019</year><date-in-citation content-type="access-date">2019 22 Fev</date-in-citation><comment>Available from: <ext-link ext-link-type="uri" xlink:href="datasus.saude.gov.br">datasus.saude.gov.br</ext-link></comment></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roques</surname><given-names>F</given-names></name><name><surname>Nashef</surname><given-names>SA</given-names></name><name><surname>Michel</surname><given-names>P</given-names></name><name><surname>Gauducheau</surname><given-names>E</given-names></name><name><surname>de Vincentiis</surname><given-names>C</given-names></name><name><surname>Baudet</surname><given-names>E</given-names></name><etal/></person-group><article-title>Risk factors and outcome in European cardiac surgery: analysis of
the EuroSCORE multinational database of 19030 patients</article-title><source>Eur J Cardiothorac Surg</source><month>6</month><year>1999</year><volume>15</volume><issue>6</issue><fpage>816</fpage><lpage>822</lpage><comment>discussion 822-3</comment><pub-id pub-id-type="pmid">10431864</pub-id></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mej&#x000ed;a</surname><given-names>OA</given-names></name><name><surname>Matrangolo</surname><given-names>BL</given-names></name><name><surname>Titinger</surname><given-names>DP</given-names></name><name><surname>Faria</surname><given-names>LB</given-names></name><name><surname>Dallan</surname><given-names>LR</given-names></name><name><surname>Galas</surname><given-names>FR</given-names></name><etal/></person-group><article-title>Age, Creatinine and Ejection Fraction Score in Brazil: Comparison
with InsCor and the EuroSCORE</article-title><source>Arq Bras Cardiol</source><month>11</month><year>2015</year><volume>105</volume><issue>5</issue><fpage>450</fpage><lpage>456</lpage><pub-id pub-id-type="doi">10.5935/abc.20150101</pub-id><comment>English, Portuguese</comment><pub-id pub-id-type="pmid">26312550</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lisboa</surname><given-names>LA</given-names></name><name><surname>Mejia</surname><given-names>OA</given-names></name><name><surname>Moreira</surname><given-names>LF</given-names></name><name><surname>Dallan</surname><given-names>LA</given-names></name><name><surname>Pomerantzeff</surname><given-names>PM</given-names></name><name><surname>Dallan</surname><given-names>LR</given-names></name><name><surname>Massoti</surname><given-names>MR</given-names></name><name><surname>Jatene</surname><given-names>FB</given-names></name></person-group><article-title>EuroSCORE II and the importance of a local model, InsCor and the
future SP-SCORE</article-title><source>Rev Bras Cir Cardiovasc</source><season>Jan-Mar</season><year>2014</year><volume>29</volume><issue>1</issue><fpage>1</fpage><lpage>8</lpage><comment>English, Portuguese</comment><pub-id pub-id-type="pmid">24896156</pub-id></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Santos</surname><given-names>CA</given-names></name><name><surname>Oliveira</surname><given-names>MA</given-names></name><name><surname>Brandi</surname><given-names>AC</given-names></name><name><surname>Botelho</surname><given-names>PH</given-names></name><name><surname>Brandi</surname><given-names>J de C</given-names></name><name><surname>Santos</surname><given-names>MA</given-names></name><etal/></person-group><article-title>Risk factors for mortality of patients undergoing coronary artery
bypass graft surgery</article-title><source>Rev Bras Cir Cardiovasc</source><season>Oct-Dec</season><year>2014</year><volume>29</volume><issue>4</issue><fpage>513</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.5935/1678-9741.20140073</pub-id><comment>English, Portuguese</comment><pub-id pub-id-type="pmid">25714203</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miceli</surname><given-names>A</given-names></name><name><surname>Bruno</surname><given-names>VD</given-names></name><name><surname>Capoun</surname><given-names>R</given-names></name><name><surname>Romeo</surname><given-names>F</given-names></name><name><surname>Angelini</surname><given-names>GD</given-names></name><name><surname>Caputo</surname><given-names>M</given-names></name></person-group><article-title>Occult renal dysfunction: a mortality and morbidity risk factor
in coronary artery bypass grafting surgery</article-title><source>J Thorac Cardiovasc Surg</source><month>3</month><year>2011</year><volume>141</volume><issue>3</issue><fpage>771</fpage><lpage>776</lpage><pub-id pub-id-type="doi">10.1016/j.jtcvs.2010.08.016</pub-id><pub-id pub-id-type="pmid">20884025</pub-id></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nashef</surname><given-names>SA</given-names></name><name><surname>Roques</surname><given-names>F</given-names></name><name><surname>Sharples</surname><given-names>LD</given-names></name><name><surname>Nilsson</surname><given-names>J</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Goldstone</surname><given-names>AR</given-names></name><etal/></person-group><article-title>EuroSCORE II</article-title><source>Eur J Cardiothorac Surg</source><month>4</month><year>2012</year><volume>41</volume><issue>4</issue><fpage>734</fpage><lpage>744</lpage><pub-id pub-id-type="doi">10.1093/ejcts/ezs043</pub-id><comment>discussion 744-5</comment><pub-id pub-id-type="pmid">22378855</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machado</surname><given-names>MN</given-names></name><name><surname>Nakazone</surname><given-names>MA</given-names></name><name><surname>Maia</surname><given-names>LN</given-names></name></person-group><article-title>Acute kidney injury based on KDIGO (Kidney Disease Improving
Global Outcomes) criteria in patients with elevated baseline serum
creatinine undergoing cardiac surgery</article-title><source>Rev Bras Cir Cardiovasc</source><season>Jul-Sep</season><year>2014</year><volume>29</volume><issue>3</issue><fpage>299</fpage><lpage>307</lpage><pub-id pub-id-type="pmid">25372901</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yehia</surname><given-names>M</given-names></name><name><surname>Collins</surname><given-names>JF</given-names></name><name><surname>Beca</surname><given-names>J</given-names></name></person-group><article-title>Acute renal failure in patients with pre-existing renal
dysfunction following coronary artery bypass grafting</article-title><source>Nephrology (Carlton)</source><month>12</month><year>2005</year><volume>10</volume><issue>6</issue><fpage>541</fpage><lpage>543</lpage><pub-id pub-id-type="pmid">16354234</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rampersad</surname><given-names>PP</given-names></name><name><surname>Udell</surname><given-names>JA</given-names></name><name><surname>Zawi</surname><given-names>R</given-names></name><name><surname>Ouzounian</surname><given-names>M</given-names></name><name><surname>Overgaard</surname><given-names>CB</given-names></name><name><surname>Sharma</surname><given-names>V</given-names></name><etal/></person-group><article-title>Preoperative Intraaortic Balloon Pump Improves Early Outcomes
Following High-Risk Coronary Artery Bypass Graft Surgery: A Meta-Analysis of
Randomized Trials and Prospective Study Design</article-title><source>J Invasive Cardiol</source><month>1</month><year>2018</year><volume>30</volume><issue>1</issue><fpage>2</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">28915508</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taniguchi</surname><given-names>FP</given-names></name><name><surname>Souza</surname><given-names>AR</given-names></name><name><surname>Martins</surname><given-names>AS</given-names></name></person-group><article-title>Cardiopulmonary bypass time as a risk factor for acute renal
failure</article-title><source>Rev Bras Cir Cardiovasc</source><season>Apr-Jun</season><year>2007</year><volume>22</volume><issue>2</issue><fpage>201</fpage><lpage>205</lpage><comment>English, Portuguese</comment><pub-id pub-id-type="pmid">17992325</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodrigues</surname><given-names>AJ</given-names></name><name><surname>Evora</surname><given-names>PR</given-names></name><name><surname>Bassetto</surname><given-names>S</given-names></name><name><surname>Alves J&#x000fa;nior</surname><given-names>L</given-names></name><name><surname>Scorzoni Filho</surname><given-names>A</given-names></name><name><surname>Ara&#x000fa;jo</surname><given-names>WF</given-names></name><etal/></person-group><article-title>Risk factors for acute renal failure after heart
surgery</article-title><source>Rev Bras Cir Cardiovasc</source><season>Oct-Dec</season><year>2009</year><volume>24</volume><issue>4</issue><fpage>441</fpage><lpage>446</lpage><comment>English, Portuguese</comment><pub-id pub-id-type="pmid">20305915</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machado</surname><given-names>MN</given-names></name><name><surname>Nakazone</surname><given-names>MA</given-names></name><name><surname>Maia</surname><given-names>LN</given-names></name></person-group><article-title>Prognostic value of acute kidney injury after cardiac surgery
according to kidney disease: improving global outcomes definition and
staging (KDIGO) criteria</article-title><source>PLoS One</source><day>14</day><month>5</month><year>2014</year><volume>9</volume><issue>5</issue><elocation-id>e98028</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0098028</pub-id><pub-id pub-id-type="pmid">24826910</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Neal</surname><given-names>JB</given-names></name><name><surname>Shaw</surname><given-names>AD</given-names></name><name><surname>Billings 4th</surname><given-names>FT</given-names></name></person-group><article-title>Acute kidney injury following cardiac surgery: current
understanding and future directions</article-title><source>Crit Care</source><day>04</day><month>7</month><year>2016</year><volume>20</volume><issue>1</issue><fpage>187</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1186/s13054-016-1352-z</pub-id><pub-id pub-id-type="pmid">27373799</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stamou</surname><given-names>SC</given-names></name><name><surname>Hill</surname><given-names>PC</given-names></name><name><surname>Dangas</surname><given-names>G</given-names></name><name><surname>Pfister</surname><given-names>AJ</given-names></name><name><surname>Boyce</surname><given-names>SW</given-names></name><name><surname>Dullum</surname><given-names>MK</given-names></name><etal/></person-group><article-title>Stroke after coronary artery bypass: incidence, predictors, and
clinical outcome</article-title><source>Stroke</source><month>7</month><year>2001</year><volume>32</volume><issue>7</issue><fpage>1508</fpage><lpage>1513</lpage><pub-id pub-id-type="pmid">11441193</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>PK</given-names></name></person-group><article-title>Predicting and preventing adverse neurologic outcomes with
cardiac surgery</article-title><source>J Card Surg</source><season>Mar-Apr</season><year>2006</year><volume>21</volume><issue>Suppl 1</issue><fpage>S15</fpage><lpage>S19</lpage><pub-id pub-id-type="pmid">16492292</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naughton</surname><given-names>C</given-names></name><name><surname>Feneck</surname><given-names>RO</given-names></name><name><surname>Roxburgh</surname><given-names>J</given-names></name></person-group><article-title>Early and late predictors of mortality following on-pump coronary
artery bypass graft surgery in the elderly as compared to a younger
population</article-title><source>Eur J Cardiothorac Surg</source><month>10</month><year>2009</year><volume>36</volume><issue>4</issue><fpage>621</fpage><lpage>627</lpage><pub-id pub-id-type="doi">10.1016/j.ejcts.2009.04.066</pub-id><pub-id pub-id-type="pmid">19540130</pub-id></element-citation></ref></ref-list></back></article>